RecruitingPhase 2NCT06373211

Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

Studying Paraneoplastic sensory ganglionopathy

Last synced from ClinicalTrials.gov May 16, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigator: Dimitri Psimaras, MD
Assistance Publique - Hôpitaux de Paris
Intervention: Immunoglobulins IV (CLAYRIG)(drug)
Enrollment: 21 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (1)

Hôpital Pitié-Salpêtrière, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06373211 on ClinicalTrials.gov

← Back to all trials